Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arvinas Holding Company ( (ARVN) ) has shared an announcement.
On May 1, 2026, Arvinas and partner Pfizer announced that the U.S. Food and Drug Administration approved VEPPANU (vepdegestrant) for adults with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine-based therapy. The approval came ahead of the June 5, 2026 PDUFA date and is based on the Phase 3 VERITAC-2 trial, in which VEPPANU significantly improved progression-free survival versus fulvestrant with mostly low-grade adverse events.
VEPPANU is the first and only FDA-approved PROTAC protein degrader, marking Arvinas’s first approved medicine and a milestone for the targeted protein degradation field, while offering a new oral option for patients facing endocrine resistance and limited second-line choices. The decision triggers a $50 million development milestone payment from Pfizer to Arvinas, net of amounts owed to Yale University under a license agreement, and the partners plan to appoint a third-party commercialization partner to maximize VEPPANU’s market potential.
The most recent analyst rating on (ARVN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, significant cash burn, and 2025 gross profit anomaly) and bearish technical signals (below key moving averages with negative MACD). Pipeline and catalyst messaging (earnings call and ARV-102 Phase 1 update) provide support but are tempered by the sharply reduced cash position and execution/partnering risk.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation therapies, including its proprietary PROteolysis Targeting Chimera (PROTAC) platform. Working with partner Pfizer Inc., Arvinas develops novel oncology, neurodegenerative, and neuromuscular treatments, aiming to address diseases driven by pathogenic proteins and resistance to existing therapies.
Average Trading Volume: 827,511
Technical Sentiment Signal: Strong Sell
Current Market Cap: $633.2M
For an in-depth examination of ARVN stock, go to TipRanks’ Overview page.